Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Antiinflammatory glucocorticoid (GC) injections are extensively used to treat painful tendons. However, GC cause severe tissue wasting in other collagen-producing tissues such as skin and bone. The objective of this study was to determine the effects of GC on tenocytes and to explore strategies to protect against unwanted side effects of GC treatment. Cell survival, collagen production, and the induction of signaling pathways in primary human tenocytes treated with dexamethasone (Dex) were assessed. Antioxidant and growth factor approaches to protection were tested. Dex treatment resulted in reduced viable cell number, cell proliferation, and collagen production. Dex induced reactive oxygen species generation in tenocytes and strongly up-regulated the stress-response transcription factors FOXO1 and FOXO3A. Phosphorylation of ERK and protein kinase B/Akt, which regulate cell proliferation and also inhibit forkhead activity, was decreased. Chemical inhibition of ERK or Akt activity significantly reduced tenocyte cell number. Ameliorating the Dex-induced reduction in ERK or Akt activity by cotreatment with vitamin C or insulin protected against the Dex-induced reduction in cell number. Silencing FOXO1 prevented the Dex-induced reduction in collagen 1α1 expression. Cotreatment with vitamin C or insulin protected against the Dex-induced increase in FOXO and the Dex-induced inhibition of collagen 1α1 expression. Reduced ERK and Akt activation and increased forkhead signaling contribute to the negative effects of GC on tenocytes. Cotreatment therapies that target these signaling pathways are protective. Vitamin C in particular may be a clinically useable co-therapy to reduce connective tissue side effects associated with GC therapy.

Original publication

DOI

10.1210/en.2010-1087

Type

Journal article

Journal

Endocrinology

Publication Date

02/2011

Volume

152

Pages

503 - 514

Keywords

Adult, Anti-Inflammatory Agents, Apoptosis, Ascorbic Acid, Blotting, Western, Cell Proliferation, Cell Survival, Cells, Cultured, Collagen, Dexamethasone, Extracellular Signal-Regulated MAP Kinases, Female, Forkhead Box Protein O1, Forkhead Box Protein O3, Forkhead Transcription Factors, Glucocorticoids, Glycosaminoglycans, Humans, Immunohistochemistry, Insulin, Male, Middle Aged, Phosphorylation, Proto-Oncogene Proteins c-akt, RNA, Small Interfering, Reactive Oxygen Species, Reverse Transcriptase Polymerase Chain Reaction, Signal Transduction